SGAs After the Clozapine REMS: Choosing Wisely

Generated October 2026 · Clinical Deep Dive0 CommentsFor 30 years, the single most effective antipsychotic in psychiatry sat behind the heaviest monitoring burden in the field. That changed on June 13, 2025, when the FDA formally removed the Risk Evaluation and Mitigation Strategy (REMS) for clozapine, ending mandatory enrollment and centralized absolute neutrophil count (ANC) reporting for prescribers, pharmacies, and patients. FDAThe agency's own advisory committees had voted nearly unanimously that the clozapine REMS no longer measurably reduced the risk of severe neutropenia beyond what labeling alone accomplishes, and that its administrative burden was suppressing use of the only agent proven superior for treatment-resistant schizophrenia. Psychiatric Times +1Clozapine's efficacy advantage in treatment-resistant illness is not new: it was established in a landmark 1988 trial and later extended to suicide-risk reduction. Arch Gen Psychiatry +1 What is new is that the access barrier keeping many patients off clozapine is gone, while ANC monitoring remains clinically recommended under the label. FDAThat single regulatory change reopens a question about the entire cohort of nine D2/5-HT2A antagonist second-generation antipsychotics (SGAs) — agents that share a mechanism of combined dopamine D2 and serotonin 5-HT2A receptor blockade — now that access and monitoring burden no longer distinguish clozapine from the rest of the class, what actually should drive agent selection among clozapine, risperidone, paliperidone, olanzapine, quetiapine, ziprasidone, asenapine, iloperidone, and lurasidone?This Deep Dive works through that question using the current FDA labeling for all 21 branded products across these nine molecules, the pivotal trials that anchor the class's efficacy and safety claims, and the 2020 APA schizophrenia guideline. Am J PsychiatryThe short answer: no single factor decides agent selection in this class. Metabolic liability, QTc/Torsades de Pointes risk, prolactin and EPS/akathisia burden, sedation and orthostasis, formulation and route, drug interactions, organ-function considerations, and adherence all remain live differentiators; what has changed is that access and monitoring burden no longer belong on that list for clozapine the way they did before June 2025.By the Numbers: What ChangedClozapine REMS operated from September 2015 to June 13, 2025 — nearly 10 years of mandatory centralized ANC reporting before elimination. FDAThe class now spans 9 molecules and 21 distinct branded products in the US, once long-acting injectable (LAI), transdermal, and combination formulations are counted. Clozaril PI +8Clozapine remains the only agent in the class FDA-approved for treatment-resistant schizophrenia and for reducing recurrent suicidal behavior. Clozaril PIDEEP DIVE:Choosing Among Nine D2/5-HT2A Antagonist AntipsychoticsMedscape Medical News © 2026 WebMD, LLCSend comments and news tips to news@medscape.net. Cite this: The Clozapine REMS Is Gone. Here's How to Rethink the Other Eight D2/5-HT2A Antipsychotics Too - Medscape- October 07, 2026.